Zobrazeno 1 - 10
of 20
pro vyhledávání: '"J C, Martínez Castrillo"'
Autor:
D. Santos García, T. De Deus Fonticoba, J. M. Paz González, C. Cores Bartolomé, L. Valdés Aymerich, J. G. Muñoz Enríquez, E. Suárez, S. Jesús, M. Aguilar, P. Pastor, L. L. Planellas, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. A. Ávila Rivera, M. J. Catalán, V. Nogueira, V. Puente, J. M. García Moreno, C. Borrué, B. Solano Vila, M. Álvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo Padilla, J. C. Martínez Castrillo, P. Sánchez Alonso, M. G. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Blázquez Estrada, M. Seijo, J. Rúiz Martínez, C. Valero, M. Kurtis, O. de Fábregues, J. González Ardura, C. Ordás, L. López Díaz, P. Mir, P. Martinez-Martin, COPPADIS Study Group
Publikováno v:
Parkinson's Disease, Vol 2021 (2021)
Introduction. In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H
Externí odkaz:
https://doaj.org/article/59a6353979e04f60ae4c6dfc6d5fa628
Autor:
N, López-Ariztegui, M, Mata-Alvarez Santullano, I, Tegel, F, Almeida, P, Sarasa, R, Rojo, F, Rico-Villademoros, J, Abril-Jaramillo, P, Bermejo, C, Borrue, N, Caballol, M, Campins-Romeu, P, Clavero, J, García-Caldentey, V, Gómez-Mayordomo, C, Labandeira, G, Martí-Andrés, J C, Martínez-Castrillo, J, Martinez-Poles, T, Muñoz, J M, Salom, C, Valderrama-Martín, A, Vinagre-Aragón
Publikováno v:
Revista de neurologia. 73(s02)
Opicapone is a catechol-O-methyl-transferase (iCOMT) inhibitor authorized in Europe in 2016 and indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose moto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::62d0c68c168340548fa79dacbf2d2ba8
https://pubmed.ncbi.nlm.nih.gov/34897643
https://pubmed.ncbi.nlm.nih.gov/34897643
Publikováno v:
Revista de neurologia. 72(9)
Apomorphine, a D1-D2 dopamine agonist, is the oldest drug with proven efficacy in the treatment of Parkinson's disease (PD), and the only with similar symptomatic power to levodopa. Its usefulness in the control of motor fluctuations, both as intermi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3a5b5e22edee7a2f44e78b35004c9aba
https://pubmed.ncbi.nlm.nih.gov/33908619
https://pubmed.ncbi.nlm.nih.gov/33908619
Autor:
A, Rodríguez-Sanz, E, Peña-Llamas, A, Alonso-Cánovas, F A, Alonso-Frech, C, Borrue-Fernández, M J, Catalán, S, Fanjul-Arbós, E, García-Cobos, R, García-Ramos, P, García Ruiz-Espiga, J, Herreros-Rodríguez, M, Kurtis-Urra, J J, López-Lozano, L, López-Manzanares, J C, Martínez-Castrillo, R, Martínez-Fernández, M, Mata, J R, Pérez-Sánchez, I J, Posada, A, Rojo, J P, Romero-Muñoz, C, Ruiz-Huete, M P, Sánchez-Alonso, F, Vivancos-Matellano, En Representación Del Grupo de Trastornos Del Movimiento de la Asociación Madrileña de Neurología, En Representación Del Grupo de Trastornos Del Movimiento de la Asociación Madrileña de Neurología
Publikováno v:
Revista de neurologia. 71(11)
Motor fluctuations are one of the most common complications of Parkinson's disease and their treatment is still a complex matter. Therefore, from the Neurology Movement Disorders Group we present our clinical experience in the treatment of these comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1f50ea96b245b797842f95be9c88c03
https://pubmed.ncbi.nlm.nih.gov/33205387
https://pubmed.ncbi.nlm.nih.gov/33205387
Autor:
G, Linazasoro-Cristóbal, L J, López Del Val, P, García Ruiz-Espiga, L, López-Manzanares, M R, Luquin-Piudo, J C, Martínez-Castrillo, P, Mir, J, Pagonabarraga-Mora
Publikováno v:
Revista de neurologia. 70(s01)
Motor fluctuations are frequently seen in Parkinson disease patients on chronic treatment with levodopa. Management of motor fluctuation includes the addition of catechol-O-methyl transferase (COMT) inhibitors. Opicapone is a recent and selective thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::255006cb2cb5d3b3d56f8ad45a5f1944
https://pubmed.ncbi.nlm.nih.gov/32515486
https://pubmed.ncbi.nlm.nih.gov/32515486
Publikováno v:
Revista de Neurología. 72:323
Introduccion. La apomorfina, agonista dopaminergico D1 y D2, es el farmaco mas antiguo con efectividad en el tratamiento de la enfermedad de Parkinson (EP) y el unico de potencia analoga a la levodopa. Su utilidad, tanto en la administracion intermit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab2dd83f69c0781ddb1046e2b011264d
https://doi.org/10.33588/rn.7209.2020658
https://doi.org/10.33588/rn.7209.2020658
Autor:
D, Santos García, S, Jesús, M, Aguilar, L L, Planellas, J, García Caldentey, N, Caballol, I, Legarda, J, Hernández Vara, I, Cabo, L, López Manzanares, I, González Aramburu, M A, Ávila Rivera, M J, Catalán, L, López Díaz, V, Puente, J M, García Moreno, C, Borrué, B, Solano Vila, M, Álvarez Sauco, L, Vela, S, Escalante, E, Cubo, F, Carrillo Padilla, J C, Martínez Castrillo, P, Sánchez Alonso, M G, Alonso Losada, N, López Ariztegui, I, Gastón, J, Kulisevsky, M, Menéndez González, M, Seijo, J, Rúiz Martínez, C, Valero, M, Kurtis, O, de Fábregues-Boixar, J, González Ardura, C, Prieto Jurczynska, P, Martinez-Martin, P, Mir, M D, Villar
Publikováno v:
European journal of neurologyReferences. 26(11)
In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a3bab3ad4bea2d0ec28f53d41a36b477
https://pubmed.ncbi.nlm.nih.gov/31179586
https://pubmed.ncbi.nlm.nih.gov/31179586
Autor:
E, Viedma-Guiard, P, Agüero, L, Crespo-Araico, C, Estévez-Fraga, G, Sánchez-Díez, J L, López-Sendón, I, Aviles-Olmos, G, García-Ribas, M L, Palacios Romero, J, Masjuan Vallejo, J C, Martínez-Castrillo, A, Alonso-Cánovas
Publikováno v:
Neurologia (Barcelona, Spain). 33(2)
The clinical problems of patients with movement disorders (MD) are complex, and the duration and frequency of face-to-face consultations may be insufficient to meet their needs. We analysed the implementation of an e-mail-based query service for our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8b009a70a7a69dae344de9435e9b81fb
https://pubmed.ncbi.nlm.nih.gov/27474365
https://pubmed.ncbi.nlm.nih.gov/27474365
Autor:
E, Peña, M, Mata, L, López-Manzanares, M, Kurtis, M, Eimil, J C, Martínez-Castrillo, I, Navas, I J, Posada, C, Prieto, C, Ruíz-Huete, L, Vela, B, Venegas
Publikováno v:
Neurologia (Barcelona, Spain).
Although antidepressants are widely used in Parkinson's disease (PD), few well-designed studies to support their efficacy have been conducted.These clinical guidelines are based on a review of the literature and the results of an AMN movement disorde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f93ed1201ea4e8e9174fcc6665e8592d
https://pubmed.ncbi.nlm.nih.gov/27004670
https://pubmed.ncbi.nlm.nih.gov/27004670
Autor:
A, Alonso Cánovas, R, Luquin Piudo, P, García Ruiz-Espiga, J A, Burguera, V, Campos Arillo, A, Castro, G, Linazasoro, J, López Del Val, L, Vela, J C, Martínez Castrillo
Publikováno v:
Neurologia (Barcelona, Spain). 29(4)
Non-ergoline dopamine agonists (DA) are effective treatments for Parkinson's disease (PD). This review presents the pharmacology, evidence of efficacy and safety profile of pramipexole, ropinirole, and rotigotine, and practical recommendations are gi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::349178bd49ada4e47fafbbac6f8014c9
https://pubmed.ncbi.nlm.nih.gov/21724302
https://pubmed.ncbi.nlm.nih.gov/21724302